Linus Biotechnology has filed a notice of an exempt offering of securities to raise $7,999,997.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Linus Biotechnology is raising $7,999,997.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Manish Arora played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Linus Biotechnology
Our mission is to improve human health through environmental biodynamics. Linus Biotechnology is a patient-centric, precision exposome medicine company headquartered in New York, NY. Originating from the worlds leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing by trailblazing researchers Drs. Manish Arora, Christine Austin and Paul Curtin. The Companys program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

To learn more about Linus Biotechnology, visit http://linusbio.com/

Contact:
Manish Arora, Chief Executive Officer
917-373-9740
https://www.linkedin.com/in/manish-arora-049476267

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.